Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J. Piper‐Vallillo, Hollis Viray, Adeel Khan, Deepa Rangachari, Daniel B. Costa
Abstract
-G2032R in preclinical studies, hold promise to transform the current treatment paradigm and permit even further gains with regards to long-term outcomes in this subset of patients.
Topics & Concepts
CrizotinibROS1Lung cancerMedicineInternal medicineOncologyCancer researchCancerAdenocarcinomaMalignant pleural effusionLung Cancer Treatments and MutationsGastric Cancer Management and OutcomesLung Cancer Diagnosis and Treatment